Drug Information

Drug General Information
Drug ID
D05DZR
Former ID
DNCL002786
Drug Name
Elotuzumab
Synonyms
BMS-901608
Drug Type
Antibody
Indication Multiple myeloma [ICD9: 203; ICD10:C90] Approved [523429], [543087]
Company
Bristol-Myers Squibb
CAS Number
CAS 915296-00-3
Target and Pathway
Target(s) SLAM family member 7 (SLAMF7) (CS1) Target Info [530353], [533177]
References
Ref 523429ClinicalTrials.gov (NCT01335399) Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma. U.S. National Institutesof Health.
Ref 543087(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361).
Ref 530353Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep;8(9):2616-24.
Ref 533177Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.